A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2
RemeGen Co., Ltd.
RemeGen Co., Ltd.
Fudan University
Beijing Biostar Pharmaceuticals Co., Ltd.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Institut Paoli-Calmettes
Zhejiang Provincial People's Hospital
Shanghai Pudong Hospital
Jiangsu HengRui Medicine Co., Ltd.
Shengjing Hospital
Shengjing Hospital
NSABP Foundation Inc
Zhejiang Provincial People's Hospital
Shengjing Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
University of Kansas Medical Center
Jilin University
Zhejiang Cancer Hospital
Gruppo Oncologico Italiano di Ricerca Clinica
ChineseAMS
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ruijin Hospital
Zhejiang Cancer Hospital
Hebei Medical University Fourth Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Fudan University
Zhejiang Cancer Hospital
Institute of Cancer Research, United Kingdom
National Cancer Center, Korea
Zhejiang Cancer Hospital
Jilin University
Tianjin Medical University Cancer Institute and Hospital
Shandong Cancer Hospital and Institute
NSABP Foundation Inc
Martin-Luther-Universität Halle-Wittenberg
Zhejiang Cancer Hospital
China Breast Cancer Clinical Study Group
Cancer Research Group - Collaborative Group, Beirut, Lebanon.
Sun Yat-sen University
ChineseAMS
Karolinska University Hospital
National University Hospital, Singapore
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Russian Academy of Medical Sciences
Shandong University
Hospital Affiliated to Military Medical Science, Beijing
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National University Hospital, Singapore